tbuckley/cabot-search huggingface dataset:
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Authors: Sabine Mueller, Jason Fangusaro, Arzu Onar Thomas, Thomas S Jacques, Pratiti Bandopadhayay, Peter de Blank, Roger J Packer, Maryam Fouladi, Antoinette Schouten van Meeteren, David Jones, Arie Perry, Yoshiko Nakano, Darren Hargrave, David Riedl, Nathan J Robison, Marita Partanen, Michael J Fisher, Olaf Witt
Journal: Neuro-Oncology (2023)

Abstract Within the last few decades, we have witnessed tremendous advancements in the study of pediatric low-grade gliomas (pLGG), leading to a much-improved understanding of their molecular underpinnings. Consequently, we have achieved successful milestones in developing and implementing targeted therapeutic agents for treating these tumors. However, the community continues to face many unknowns when it comes to the most effective clinical implementation of these novel targeted inhibitors or combinations thereof. Questions encompassing optimal dosing strategies, treatment duration, methods for assessing clinical efficacy, and the identification of predictive biomarkers remain unresolved. Here, we offer the consensus of the international pLGG coalition (iPLGGc) clinical trial working group on these important topics and comment on clinical trial design and endpoint rationale. Throughout, we seek to standardize the global approach to early clinical trials (phase I and II) for pLGG, leading to more consistently interpretable results as well as enhancing the pace of novel therapy development and encouraging an increased focus on functional endpoints as well and quality of life for children faced with this disease.
Manchester Procedure vs Sacrospinous Hysteropexy for Pelvic Organ Prolapse—Reply
Authors: Rosa A. Enklaar, Sascha F. M. Schulten
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Browsing the <i>Journal of Gastrointestinal Distress</i>
Authors: Lisa Grove
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer
Authors: Tian-Jiao Zhou, Meng-Meng Zhang, Dan-Meng Liu, Li-Ling Huang, Hai-Qing Yu, Yi Wang, Lei Xing, Hu-Lin Jiang
Journal: Biomaterials (2023)
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol. 2024;85:146–53.
Authors: Rui-Cheng Wu, Deng-Xiong Li, De-Chao Feng
Journal: European Urology (2023)
Implementation of Mohs micrographic surgery at the VA New York Manhattan Harbor Healthcare System eliminated need for re-excision and decreased time to treatment: A retrospective and prospective cohort study
Authors: Jaclyn Rosenthal Himeles, Alexa Beth Steuer, Rachel Sally, Daniel Gutierrez, John G. Zampella, Mary L. Stevenson, John A. Carucci, Nayoung Lee
Journal: Journal of the American Academy of Dermatology (2023)
M1 macrophages induce PD-L1<sup>hi</sup>cell-led collective invasion in HPV-positive head and neck squamous cell carcinoma via TNF-α/CDK4/UPS14
Authors: Jiashun Wu, Xin Pang, Xiao Yang, Mei Zhang, Bingjun Chen, Huayang Fan, Haofan Wang, Xianghua Yu, Yaling Tang, Xinhua Liang
Journal: Journal for ImmunoTherapy of Cancer (2023)

Although the roles of PD-L1 in promoting tumor escape from immunosurveillance have been extensively addressed, its non-immune effects on tumor cells remain unclear. The spatial heterogeneity of PD-L1 staining in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) tissues was identified by immunohistochemistry. Three-dimensional (3D) specific cell-led invasion assay and 3D cancer spheroid model were used to investigate the roles of PD-L1hileader cells in collective invasion. The impact of M1 macrophages on specific PD-L1 expression in leader cells and its mechanisms were further studied. Finally, the effect of combination therapy of anti-PD-L1 and CDK4 inhibitor on HPV-positive tumors were evaluated on a mice model. Here, we observed a distinctive marginal pattern of PD-L1 expression in HPV-positive HNSCC tissues. By mimicking this spatial pattern of PD-L1 expression in the 3D invasion assay, we found that PD-L1hi cells led the tumor collective invasion. M1 macrophages induced specific PD-L1 expression in leader cells, and depletion of macrophages in tumor-bearing mice abrogated PD-L1hileader cells and collective invasion. Mechanistically, TNF-α secreted by M1 macrophages markedly increased the abundance of PD-L1 via CDK4/ubiquitin-specific peptidase 14-mediated deubiquitination of PD-L1. We also found that suppression of CDK4 enhanced the efficacy of anti-PD-L1 therapy in an E6/E7 murine model. Our study identified TNF-α/CDK4/ubiquitin-specific peptidase 14-mediated PD-L1 stability as a novel mechanism underlying M1 macrophage-induced PD-L1hileader cells and collective tumor invasion, and highlighted the potential of the combination therapy of anti-PD-L1 and CDK4 inhibitor for HPV-positive HNSCC.
ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3
Authors: Yong-Qiang Ao, Jian Gao, Chun Jin, Shuai Wang, Li-Cheng Zhang, Jie Deng, Zong-wei Chen, Hai-Kun Wang, Jia-Hao Jiang, Jian-Yong Ding
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Activating signal cointegrator 3 (ASCC3) has been identified as an oncogenic factor that impairs host immune defense. However, the underlying mechanisms of carcinogenesis and its impact on the antitumor immune response remain unclear. In this study, we aimed to investigate the molecular mechanisms of ASCC3 in the progression of non-small cell lung cancer (NSCLC). Methods Single-cell sequencing data from the Gene Expression Omnibus and gene expression profiles from The Cancer Genome Atlas database were analyzed. The expression, clinical relevance and biological functions of ASCC3 in NSCLC were explored. Then, RNA sequencing, immunoprecipitation, mass spectrometry, immunofluorescence, and flow cytometry analyses were conducted to explore the underlying molecular mechanisms. In addition, in vivo experiments in mouse models were conducted to explore the probability of ASCC3 knockdown to improve the efficacy of anti-Programmed Death-1 (PD-1) therapy in NSCLC. Results ASCC3 was significantly upregulated in NSCLC and correlated with poor pathological characteristics and prognosis in patients with NSCLC. Overexpression of ASCC3 promoted malignant phenotypes of NSCLC cells and induced an immunosuppressive tumor microenvironment, which was characterized by a decrease in CD8 + T cells, natural killer cells and dendritic cells but an increase in regulatory T(Treg) cells. Mechanistically, ASCC3 stabilized signal transducer and activator of transcription (STAT)3 signaling by recruiting Cullin-associated and neddylation dissociated 1 (CAND1), which inhibited ubiquitin-mediated degradation of STAT3, thereby impairing the type I interferon response of tumor cells and promoting the immunosuppression and progression of NSCLC. Furthermore, high expression of ASCC3 impaired the efficacy of anti-PD-1 therapy, and an anti-PD-1 antibody combined with ASCC3 knockdown exerted promising synergistic efficacy in a preclinical mouse model. Conclusion ASCC3 could stabilize the STAT3 pathway via CAND1, reshaping the tumor microenvironment and inducing resistance to anti-PD-1 therapy, which promotes the progression of NSCLC. It is a reliable prognostic indicator and can be a target in combination therapy for NSCLC.
Photonic control of ligand nanospacing in self-assembly regulates stem cell fate
Authors: Sungkyu Lee, Jounghyun Yoo, Gunhyu Bae, Ramar Thangam, Jeongyun Heo, Jung Yeon Park, Honghwan Choi, Chowon Kim, Jusung An, Jungryun Kim, Kwang Rok Mun, Seungyong Shin, Kunyu Zhang, Pengchao Zhao, Yuri Kim, Nayeon Kang, Seong-Beom Han, Dahee Kim, Jiwon Yoon, Misun Kang, Jihwan Kim, Letao Yang, Solmaz Karamikamkar, Jinjoo Kim, Yangzhi Zhu, Alireza Hassani Najafabadi, Guosheng Song, Dong-Hwee Kim, Ki-Bum Lee, Soong Ju Oh, Hyun-Do Jung, Hyun-Cheol Song, Woo Young Jang, Liming Bian, Zhiqin Chu, Juyoung Yoon, Jong Seung Kim, Yu Shrike Zhang, Yongju Kim, Ho Seong Jang, Sehoon Kim, Heemin Kang
Journal: Bioactive Materials (2023)

Extracellular matrix (ECM) undergoes dynamic inflation that dynamically changes ligand nanospacing but has not been explored. Here we utilize ECM-mimicking photocontrolled supramolecular ligand-tunable Azo
Baicalin-peptide supramolecular self-assembled nanofibers effectively inhibit ferroptosis and attenuate doxorubicin-induced cardiotoxicity
Authors: Yinghua Zeng, Xu Liao, Yuting Guo, Fengjiao Liu, Fan Bu, Jie Zhan, Jianwu Zhang, Yanbin Cai, Mingzhi Shen
Journal: Journal of Controlled Release (2024)
Apigenin-7-glucoside-loaded nanoparticle alleviates intestinal ischemia-reperfusion by ATF3/SLC7A11-mediated ferroptosis
Authors: Xuerong Zhao, Zhuoya Wang, Guanlin Wu, Lianhong Yin, Lina Xu, Ning Wang, Jinyong Peng
Journal: Journal of Controlled Release (2024)
Hydrogel design to overcome thermal resistance and ROS detoxification in photothermal and photodynamic therapy of cancer
Authors: Da In Jeong, Hyun Jin Kim, Song Yi Lee, Sungyun Kim, Ji Won Huh, Jae-Hee Ahn, Mrinmoy Karmakar, Han-Jun Kim, KangJu Lee, Junmin Lee, Hyun-Jeong Ko, Hyun-Jong Cho
Journal: Journal of Controlled Release (2023)
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals
Authors: Maria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge, Stine Johansen, Johanne Kragh Hansen, Peter Andersen, Camilla Dalby Hansen, Helle Lindholm Schnefeld, Katrine Tholstrup Bech, Nikolaj Torp, Mads Israelsen, Sönke Detlefsen, Isabel Graupera, Pere Gines, Aleksander Krag, Maja Thiele
Journal: Clinical Gastroenterology and Hepatology (2023)

Background and aims: Early detection of liver fibrosis is believed to promote lifestyle changes.We evaluated self-reported changes in alcohol intake, diet, exercise, and weight after participating in a screening study for liver fibrosis. Methods:We conducted a prospective screening study of individuals at risk of alcohol related (ALD) or metabolic dysfunction-associated steatotic liver disease (MASLD).We provided lifestyle advice to all participants and evaluated lifestyle changes by questionnaires after one week and six months, with re-examination of a subgroup after two years.Results: A total of 1,850 at risk of ALD and 2,946 at risk of MASLD were included, of whom 383 (8%) were screening positive (transient elastography ≥8 kPa).Eighty-four percent replied to the 6-month questionnaire.In ALD participants, excessive drinking decreased from 46% to 32% after 6 months.Only 15% reported increased drinking, without differences between screening positive and negative individuals (p=0.698).In highrisk drinkers, a positive screening test predicted abstinence or decreased alcohol use after six months (odds ratio 2. 45, 1.32-4.57,p=0.005).After two years, excessive drinking decreased from 52% to 41% in a subgroup of 752 individuals and a positive screening test predicted abstinence or decreased alcohol use after two years (odds ratio 1.84, 1.09-3.11,p=0.023).MASLD participants showed similar improvements: 35% improved their diet, 22% exercised more, and 13% reported a weight loss ≥5% after six months. Conclusion:Screening for liver fibrosis is associated with sustained improvements in alcohol consumption, diet, weight, and exercise in at-risk ALD and MASLD.The changes are most pronounced in screening positive participants, but not limited to this group.
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals
Authors: Ottavia M. Delmonte, Cihan Oguz, Kerry Dobbs, Katherine Myint-Hpu, Boaz Palterer, Michael S. Abers, Deborah Draper, Meng Truong, Ian M. Kaplan, Rachel M. Gittelman, Yu Zhang, Lindsey B. Rosen, Andrew L. Snow, Clifton L. Dalgard, Peter D. Burbelo, Luisa Imberti, Alessandra Sottini, Eugenia Quiros-Roldan, Francesco Castelli, Camillo Rossi, Duilio Brugnoni, Andrea Biondi, Laura Rachele Bettini, Mariella D’Angio, Paolo Bonfanti, Megan V. Anderson, Annalisa Saracino, Maria Chironna, Mariantonietta Di Stefano, Jose Ramon Fiore, Teresa Santantonio, Riccardo Castagnoli, Gian Luigi Marseglia, Mary Magliocco, Marita Bosticardo, Francesca Pala, Elana Shaw, Helen Matthews, Sarah E. Weber, Sandhya Xirasagar, Jason Barnett, Andrew J. Oler, Dimana Dimitrova, Jenna R.E. Bergerson, David H. McDermott, V. Koneti Rao, Philip M. Murphy, Steven M. Holland, Andrea Lisco, Helen C. Su, Michail S. Lionakis, Jeffrey I. Cohen, Alexandra F. Freeman, Thomas M. Snyder, Justin Lack, Luigi D. Notarangelo
Journal: Journal of Allergy and Clinical Immunology (2023)
A biomimetic cuproptosis amplifier for targeted NIR-II fluorescence/photoacoustic imaging-guided synergistic NIR-II photothermal immunotherapy
Authors: Yeneng Dai, Lipeng Zhu, Xue Li, Fengjuan Zhang, Kai Chen, Guanda Jiao, Yu Liu, Ziyi Yang, Ziang Guo, Baohong Zhang, Qingming Shen, Qi Zhao
Journal: Biomaterials (2023)
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review
Authors: Jonathan I. Silverberg, Mark Boguniewicz, Francisco J. Quintana, Rachael A. Clark, Lara Gross, Ikuo Hirano, Anna M. Tallman, Philip M. Brown, Doral Fredericks, David S. Rubenstein, Kimberly A. McHale
Journal: Journal of Allergy and Clinical Immunology (2023)

The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that has wide-ranging roles, including regulation of inflammation and homeostasis. AhR is not a cell surface receptor; rather, it exists in a cytoplasmic complex that responds to a wide variety of structurally dissimilar endogenous, microbial, and environmental ligands. The ubiquitous expression of AhR, its ability to be activated by a wide range of ligands, and its capacity to act as a master regulator for gene expression and homeostasis make it a promising new therapeutic target. Clinical trials of tapinarof cream have now validated AhR agonism as a therapeutic approach that can deliver significant efficacy for treating inflammatory skin diseases, including psoriasis and atopic dermatitis. Tapinarof 1% cream is a first-in-class, nonsteroidal, topical, AhR agonist with a pharmacokinetic profile that results in localized exposure at sites of disease, avoiding systemic safety concerns, drug interactions, or off-target effects. Psoriasis and atopic dermatitis both involve epidermal inflammation, cellular immune responses, dysregulation of skin barrier protein expression, and oxidative stress. On the basis of the clinical effectiveness of tapinarof cream for treating inflammatory skin diseases, we review how targeting AhR may offer a significant opportunity in other conditions that share key aspects of pathogenesis, including asthma, inflammatory bowel disease, eosinophilic esophagitis, ophthalmic, and nervous system diseases.
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma
Authors: Jia Luo, Michelle Sanchez, Elinton Lee, Hans Hertzler, Nhi Luong, Emanuele Mazzola, Bryanna Finstein, Rubii Tamen, Gifty Brisbane, Tom Nguyen, Paul K. Paik, Jamie E. Chaft, Michael L. Cheng, Hassan Khalil, Sarina A. Piha-Paul, Lynette M. Sholl, Mizuki Nishino, Pasi A. Jänne, Steven G. DuBois, Glenn J. Hanna, Geoffrey I. Shapiro, Christopher A. French
Journal: Journal of Thoracic Oncology (2023)
Persistent esophageal changes after histologic remission in eosinophilic esophagitis
Authors: Melanie A. Ruffner, Tetsuo Shoda, Megha Lal, Zoe Mrozek, Amanda B. Muir, Jonathan M. Spergel, Evan S. Dellon, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2023)
Per- and Poly-Fluoroalkyl Substances Exposure Is Associated With Later Occurrence of Inflammatory Bowel Disease
Authors: Manasi Agrawal, Vishal Midya, Amith Maroli, Jared Magee, Lauren Petrick, Jean-Frederic Colombel, None Damaskini Valvi, Ryan C. Ungaro, Georgia Dolios, Francesca Petralia, Joana Torres, Chad Porter
Journal: Clinical Gastroenterology and Hepatology (2023)
Assessment of extra-coronary peripheral arteriopathy in spontaneous coronary dissection; State of the art in non-invasive imaging techniques and future perspectives
Authors: Emmanuel Androulakis, Christos Kourek, Apostolos Vrettos, Nikolaos Kontopodis, Eirini Lioudaki, Maria Prasinou, Andreas Xanthopoulos, Alexios Antonopoulos, Alexandros Briasoulis, Raad Mohiaddin
Journal:  (2023)

Abstract Spontaneous coronary artery dissection (SCAD) has been recognized as an important cause of acute coronary syndrome in women ≤ 50 years old, and up to 43% of pregnancy-associated myocardial infarction. SCAD has a strong association with extra-coronary arteriopathies, including either more common entities such as dissections, intracranial or other aneurysms, and extra-coronary and coronary arterial tortuosity or less common inherited vascular disorders such as Ehlers–Danlos syndrome, Marfan syndrome, and Loeys–Dietz syndrome, leading to the conclusion that systemic arterial disorders may underlie SCAD. Fibromuscular dysplasia is the most common extra-coronary vascular abnormality identified among these patients, also sharing a common genetic variant with SCAD. The American Heart Association, in a scientific statement regarding the management of SCAD, recommends that patients with SCAD should undergo additional evaluation with imaging techniques including either computed tomography angiography (CTA) or magnetic resonance angiography (MRA). MRA has been shown to have sufficient diagnostic accuracy in identifying extra-coronary arterial abnormalities, almost equal to CTA and conventional angiography. The aim of this review is to appraise the most recent important evidence of extra-coronary arteriopathy in the setting of SCAD and to discuss the strengths and weaknesses of various non-invasive imaging methods for screening of extra-coronary arteriopathies in patients with SCAD.
Inferring Viral Transmission Time from Phylogenies for Known Transmission Pairs
Authors: Emma E Goldberg, Erik J Lundgren, Ethan O Romero-Severson, Thomas Leitner
Journal: Molecular Biology and Evolution (2023)

When the time of an HIV transmission event is unknown, methods to identify it from virus genetic data can reveal the circumstances that enable transmission. We developed a single-parameter Markov model to infer transmission time from an HIV phylogeny constructed of multiple virus sequences from people in a transmission pair. Our method finds the statistical support for transmission occurring in different possible time slices. We compared our time-slice model results to previously described methods: a tree-based logical transmission interval, a simple parsimony-like rules-based method, and a more complex coalescent model. Across simulations with multiple transmitted lineages, different transmission times relative to the source's infection, and different sampling times relative to transmission, we found that overall our time-slice model provided accurate and narrower estimates of the time of transmission. We also identified situations when transmission time or direction was difficult to estimate by any method, particularly when transmission occurred long after the source was infected and when sampling occurred long after transmission. Applying our model to real HIV transmission pairs showed some agreement with facts known from the case investigations. We also found, however, that uncertainty on the inferred transmission time was driven more by uncertainty from time calibration of the phylogeny than from the model inference itself. Encouragingly, comparable performance of the Markov time-slice model and the coalescent model-which make use of different information within a tree-suggests that a new method remains to be described that will make full use of the topology and node times for improved transmission time inference.